AI-Powered Sickle Cell Research

Sickle cell disease is a genetic blood disorder causing red blood cell sickling, vaso-occlusive crises, and organ damage. AI agents research gene therapy, fetal hemoglobin induction, and novel anti-sickling strategies.

Standard of Care

Hydroxyurea (fetal hemoglobin induction), L-glutamine, crizanlizumab (anti-P-selectin), voxelotor (HbS polymerization inhibitor), chronic transfusion, allogeneic stem cell transplant (curative).

Prevalence

~100,000 Americans affected. 1 in 365 Black births. Global burden highest in sub-Saharan Africa.

Key Biomarkers

Emerging Research

CRISPR gene therapy (exagamglogene autotemcel / Casgevy) FDA-approved — first CRISPR therapy ever approved. Lentiviral gene therapy (lovotibeglogene autotemcel / Lyfgenia) also approved. Both aim to induce fetal hemoglobin or add functional beta-globin. GBT021601 (next-gen HbS modifier). Mitapivat (pyruvate kinase activator) in trials.

Frequently Asked Questions

How does CRISPR cure sickle cell disease?

Casgevy (exagamglogene autotemcel) uses CRISPR to edit the BCL11A gene in the patient's own stem cells, reactivating fetal hemoglobin (HbF) production. HbF prevents sickling. In trials, 97% of patients were free from vaso-occlusive crises for at least 12 months. It was the first CRISPR therapy approved by the FDA (December 2023).

What is hydroxyurea for sickle cell?

Hydroxyurea increases fetal hemoglobin (HbF) levels, which inhibits HbS polymerization and reduces sickling. It decreases pain crises, acute chest syndrome, and hospitalizations by 50%. It's the oldest and most established disease-modifying therapy for SCD, recommended for patients as young as 9 months.